New IBD drug candidate begins first human safety tests
NCT ID NCT07373457
First seen Jan 30, 2026 · Last updated May 24, 2026 · Updated 21 times
Summary
This early-stage study tests an experimental drug called HW201877 in 104 healthy adults to see if it is safe and how the body handles it. The drug is being developed for inflammatory bowel disease (IBD). Participants will receive either the drug or a placebo, and researchers will monitor side effects and measure drug levels in the body. This is a first step to find a safe dose before testing in patients with IBD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.